Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Steady progress over four decades toward understanding the pathogenesis and clinical
consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Background Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at high
risk of liver-related and all-cause morbidity and mortality. We investigated the efficacy and …

Non-alcoholic fatty liver disease (NAFLD) and its inflammatory form, non-alcoholic
steatohepatitis (NASH), have quickly risen to become the most prevalent chronic liver …

Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver
disease. There has been important progress in the field in recent years and the complexity of …

Artificial intelligence has the potential to revolutionize modern society in all its aspects.
Encouraged by the variety and vast amount of data that can be gathered from patients (eg …

Background & Aims Non-alcoholic steatohepatitis (NASH) is associated with increased risk
of liver-related and cardiovascular morbidity and mortality. Given the complex …

Advances in digitizing tissue slides and the fast-paced progress in artificial intelligence,
including deep learning, have boosted the field of computational pathology. This field holds …

Clinical routine in hepatology involves the diagnosis and treatment of a wide spectrum of
metabolic, infectious, autoimmune and neoplastic diseases. Clinicians integrate qualitative …